Eiger BioPharmaceuticals, Inc. (EIGR) Expected to Post Earnings of -$1.27 Per Share
Brokerages expect that Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) will announce earnings of ($1.27) per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Eiger BioPharmaceuticals’ earnings. The highest EPS estimate is ($1.04) and the lowest is ($1.39). Eiger BioPharmaceuticals reported earnings per share of ($1.49) in the same quarter last year, which suggests a positive year-over-year growth rate of 14.8%. The firm is expected to announce its next quarterly earnings results on Tuesday, November 14th.
According to Zacks, analysts expect that Eiger BioPharmaceuticals will report full-year earnings of ($5.35) per share for the current year, with EPS estimates ranging from ($5.52) to ($5.19). For the next year, analysts anticipate that the firm will report earnings of ($5.02) per share, with EPS estimates ranging from ($5.86) to ($4.44). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that follow Eiger BioPharmaceuticals.
Eiger BioPharmaceuticals (NASDAQ:EIGR) last announced its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($1.33) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.28) by ($0.05).
A number of equities analysts recently commented on the company. Wedbush reaffirmed an “ourperform” rating and issued a $34.00 target price on shares of Eiger BioPharmaceuticals in a report on Monday, August 14th. Zacks Investment Research cut Eiger BioPharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, August 16th. BTIG Research assumed coverage on Eiger BioPharmaceuticals in a report on Friday, July 14th. They issued a “buy” rating and a $32.00 target price on the stock. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $36.00 target price on shares of Eiger BioPharmaceuticals in a report on Tuesday, August 15th. Finally, ValuEngine raised Eiger BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. Eiger BioPharmaceuticals currently has a consensus rating of “Buy” and an average price target of $30.43.
In other Eiger BioPharmaceuticals news, Director Jeffrey S. Glenn purchased 15,000 shares of the stock in a transaction that occurred on Friday, September 1st. The stock was purchased at an average price of $9.53 per share, with a total value of $142,950.00. Following the acquisition, the director now owns 31,355 shares in the company, valued at $298,813.15. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 28.80% of the stock is currently owned by company insiders.
Large investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp lifted its holdings in shares of Eiger BioPharmaceuticals by 4.7% in the 1st quarter. Bank of New York Mellon Corp now owns 13,696 shares of the biotechnology company’s stock valued at $157,000 after acquiring an additional 614 shares during the last quarter. Susquehanna International Group LLP bought a new position in shares of Eiger BioPharmaceuticals in the 2nd quarter valued at about $114,000. LMR Partners LLP bought a new position in shares of Eiger BioPharmaceuticals in the 2nd quarter valued at about $116,000. Goldman Sachs Group Inc. bought a new position in shares of Eiger BioPharmaceuticals in the 2nd quarter valued at about $272,000. Finally, Hikari Power Ltd lifted its holdings in shares of Eiger BioPharmaceuticals by 491.0% in the 2nd quarter. Hikari Power Ltd now owns 60,992 shares of the biotechnology company’s stock valued at $482,000 after acquiring an additional 50,672 shares during the last quarter. 59.94% of the stock is owned by hedge funds and other institutional investors.
Shares of Eiger BioPharmaceuticals (NASDAQ EIGR) traded down 9.37% during trading on Monday, hitting $11.60. The stock had a trading volume of 61,850 shares. Eiger BioPharmaceuticals has a 1-year low of $6.10 and a 1-year high of $14.56. The firm’s market capitalization is $97.06 million. The stock’s 50-day moving average price is $11.38 and its 200 day moving average price is $8.76.
WARNING: This news story was first reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/23/eiger-biopharmaceuticals-inc-eigr-expected-to-post-earnings-of-1-27-per-share.html.
Eiger BioPharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eiger BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.